|Bid||9.30 x 200|
|Ask||16.50 x 100|
|Day's Range||10.24 - 10.86|
|52 Week Range||5.42 - 25.95|
|PE Ratio (TTM)||N/A|
|Earnings Date||Aug 9, 2017 - Aug 14, 2017|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||17.69|
While Zynerba's share price is still roughly half of last year's peak, the company has gotten attention from Wall Street with big upside in analyst calls in recent days.
-Focusing Strategy on Rare and Near-Rare Neurological and Psychiatric Disorders-. -Pediatric Neurologist Liza Squires, M.D. Joins as Chief Medical Officer-.
Experts expect a serious cannabis shortage as Canada looks to legalize recreational cannabis in 2018, creating huge opportunities for savvy investors
For investors, increase in profitability and industry-beating performance can be essential considerations in an investment. Below, I will examine Zynerba Pharmaceuticals Inc’s (NASDAQ:ZYNE) track record on a high level, toRead More...
NEW YORK, NY / ACCESSWIRE / December 5, 2017 / U.S. markets saw mixed Monday as the Dow reached a new record after investors celebrated the passing of a bill to overhaul the country's tax system while ...
Shares of Zynerba Pharmaceuticals Inc (NASDAQ: ZYNE ), a specialty pharmaceutical company that focuses on developing and commercializing pharmaceutically produced transdermal cannabinoid treatments, traded ...
-Clinically Meaningful Median Reduction in Seizures Compared to Baseline of 48% to 65% Achieved with Continued ZYN002 Treatment in STAR 2 Extension Study–. -Data Help Clarify Protocol Design for Planned ...
Zynerba Pharmaceuticals Inc (NASDAQ:ZYNE), a pharmaceuticals company based in United States, received a lot of attention from a substantial price increase on the NasdaqGM in the over the last fewRead More...
On a per-share basis, the Devon, Pennsylvania-based company said it had a loss of 63 cents. The results fell short of Wall Street expectations. The average estimate of four analysts surveyed by Zacks Investment ...
The Street reacted to Zynerba Pharmaceuticals Inc (NASDAQ: ZYNE )’s positive Fragile X trial results with marked ambivalence. Investors propelled the stock 76 percent higher even as biotech and behavioral ...
Microchip Technology, United Continental and Zynerba Pharmaceuticals highlighted as Zacks Bull and Bear of the Day
NEW YORK, NY / ACCESSWIRE / September 29, 2017 / Zynerba scored a big win yesterday after announcing positive results from its trial of ZYN002, a cannabidiol gel that is aimed to reduce symptoms of fragile ...
On Thursday, shares of clinical-stage specialty pharmaceutical company Zynerba Pharmaceuticals (ZYNE) are soaring, up nearly 54% in afternoon trading after it announced positive results in a mid-stage study of its cannabis-derived gel treatment.
Zynerba Pharmaceuticals shares saw a huge gain early on Thursday after the firm announced positive results from its mid-stage cannabinoid trial.